Drugs / BA1302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06596915 | Sep 2024 → Dec 2025 overdue | breast cancer, melanoma, non-small cell lung carcinoma, pancreatic adenocarcinoma | Shandong Boan Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BA1302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06596915 ↗ |
| Route | Intravenous | “BA1302 administered intravenously” NCT06596915 ↗ |